Bortezomib
C05013
Phase 2 small_molecule completed
Quick answer
Bortezomib for Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL) is a Phase 2 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed